Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage biotechnology company revolutionizing the field of drug discovery. By integrating technological innovations across biology, chemistry, automation, data science, and engineering, Recursion aims to decode biology and industrialize the drug discovery process.
Founded with a vision to radically improve patient lives, Recursion has developed a powerful drug discovery platform capable of conducting millions of rapid, automated experiments. This platform leverages the Recursion Operating System (OS), a sophisticated data and machine learning infrastructure, to accelerate the discovery of therapeutics, especially for rare genetic diseases.
Recent achievements include pioneering the use of machine learning in predicting protein-ligand interactions and partnering with major pharmaceutical companies like Bayer and Enamine. These collaborations have significantly enhanced Recursion's capabilities in chemical space exploration and drug discovery.
Financially, Recursion is robust, constantly expanding its dataset and computational resources, including operating one of the world's most powerful supercomputers, BioHive-2. This supercomputer, equipped with NVIDIA DGX H100 systems, significantly enhances their ability to train AI models and accelerate drug discovery.
Headquartered in Salt Lake City and with offices in Toronto, Montréal, and the San Francisco Bay Area, Recursion is a founding member of BioHive, the Utah life sciences industry collective. The company's horizontal business model focuses on discovery, allowing for cost-efficient operations by spreading risks across various therapeutic opportunities.
Significant News:
- Partnership with Enamine: Recursion announced a partnership with Enamine to leverage its MatchMaker tool for enriched screening libraries.
- Agreement with Bayer: Recursion in-licensed a novel molecule for treating fibrotic diseases from its collaboration with Bayer.
- Launch of LOWE: Demonstrated LOWE, an LLM-based software for drug discovery tasks, in collaboration with NVIDIA.
- London Expansion: Opened a new office in London and appointed Michael Bronstein as a Scientific Advisor.
- First Quarter 2024 Financial Results: Reported significant progress and upcoming value catalysts in drug discovery and technology advancements.
- BioHive-2 Supercomputer: Launched BioHive-2, a top-tier supercomputer, to enhance AI model training and drug discovery processes.
- Nature Genetics Publication: Published findings on proximity bias in CRISPR-Cas9 editing and proposed a debiasing algorithm.
For more information, visit Recursion Pharmaceuticals or follow their updates on Twitter and LinkedIn.
Recursion (NASDAQ: RXRX) has received FDA Fast Track designation for its drug candidate REC-4881, aimed at treating familial adenomatous polyposis (FAP) in patients post-colectomy. This allosteric small molecule inhibitor targets MEK1 and MEK2, intended to reduce polyp burden and prevent progression to adenocarcinoma. The designation facilitates expedited drug review, enabling earlier access for patients upon approval. A Phase 2 trial for REC-4881 is set to enroll patients in Q3 2022, marking a significant step towards addressing the unmet needs in FAP treatment.
Recursion (NASDAQ: RXRX), a clinical-stage biotechnology firm, announced its participation in three upcoming investor conferences. These include the Piper Sandler AI/Machine Learning Conference on April 1, 2022, the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022, and the Berenberg Discover AI Seminar 2022 on April 26, 2022. The conferences are aimed at showcasing Recursion's advancements in drug discovery, leveraging its extensive biological and chemical datasets. Interested parties can access live webcasts via the investor section of Recursion's website.
Altitude Lab has announced that its inaugural cohort of startups has successfully raised $54 million in seed funding, marking the largest seed financing for life science startups in Utah's history. This incubation initiative, founded in partnership with Recursion and the University of Utah's PIVOT Center, focuses on supporting early-stage healthcare startups. With six out of seven startups securing financing within 18 months, the program emphasizes collaboration with biopharma and health systems, fostering growth in Utah's BioHive ecosystem.
Recursion (NASDAQ: RXRX) announced significant growth and collaborations in its press release on March 23, 2022. The company partnered with Roche and Genentech to develop up to 40 novel medicines, with an upfront payment of $150 million. Recursion expanded its collaboration with Bayer to explore over a dozen fibrosis programs. Additionally, the company initiated its Phase 2 clinical trial for CCM and advanced various oncology therapeutics. Financially, Recursion reported a net loss of $64.9 million for Q4 2021, a significant increase from the previous year.
Recursion (NASDAQ: RXRX) has achieved a significant milestone by enrolling the first patient in its Phase 2 SYCAMORE clinical trial for REC-994, a novel small molecule aimed at treating cerebral cavernous malformation (CCM). CCM affects approximately 360,000 symptomatic patients in the U.S. and EU5. The trial is a multi-center, randomized, double-blind study expected to enroll around 60 subjects, focusing on the safety, efficacy, and pharmacokinetics of REC-994. This marks the first industry-sponsored human efficacy trial for CCM, highlighting the urgent need for effective therapies in this patient population.
Recursion (NASDAQ: RXRX) updated its clinical trial guidance, including a significant delay for a Phase 2 trial of REC-3599 in Tay-Sachs disease, now expected to start in approximately two years. However, the company is on track for several other trials: REC-994 for Cerebral Cavernous Malformation, REC-2282 for Neurofibromatosis Type 2, and REC-4881 for Familial Adenomatous Polyposis, with expected patient enrollment in Q2 2022. Preparations for a Phase 1 study of REC-3964 in recurrent C. difficile colitis are also proceeding as planned, aiming for enrollment in the second half of 2022.
Recursion (NASDAQ: RXRX), a biotechnology firm focused on drug discovery, announced its participation in two major investor conferences:
- KeyBanc Capital Markets Emerging Technology Summit — March 8-9, 2022
- SVB Leerink Mountain Meeting — March 20-23, 2022
Webcasts will be accessible via the investor section on their website. Recursion utilizes advanced technologies to enhance drug discovery, boasting one of the largest biological datasets and powerful computational resources, aiming to revolutionize medicine.
Recursion (NASDAQ: RXRX) has announced its participation in the upcoming SVB Leerink 11th Annual Global Healthcare Conference from February 14 to February 18, 2022. The conference will feature webcasts accessible in the investor section of www.Recursion.com.
Recursion is a clinical-stage biotechnology firm that focuses on industrializing drug discovery by decoding biology, leveraging its extensive datasets and advanced machine-learning algorithms.
Recursion (NASDAQ: RXRX) announced an expanded collaboration with Bayer AG focusing on fibrosis. The partnership will leverage Recursion's inferential search capabilities to accelerate drug discovery and development in fibrotic diseases, increasing the total number of relevant programs to over a dozen. Each program could yield more than $100 million in milestone payments plus royalties. This collaboration builds on successful prior efforts, with Recursion aiming to operationalize drug discovery more efficiently.
FAQ
What is the current stock price of Recursion Pharmaceuticals (RXRX)?
What is the market cap of Recursion Pharmaceuticals (RXRX)?
What is Recursion Pharmaceuticals, Inc.?
What is the Recursion OS?
What recent partnerships has Recursion announced?
What technological advancements has Recursion made?
What is the significance of the BioHive-2 supercomputer?
Where is Recursion Pharmaceuticals headquartered?
What is the focus of Recursion's drug discovery efforts?
How does Recursion's business model benefit its operations?
What is the role of machine learning in Recursion's platform?
How can I learn more about Recursion Pharmaceuticals?
